Advancements in Targeted Therapies for Colorectal Cancer: Innovative Drug Formulation and Delivery Strategies
Archiv der Pharmazie,
Год журнала:
2025,
Номер
358(4)
Опубликована: Апрель 1, 2025
ABSTRACT
Colorectal
cancer
(CRC)
is
a
leading
cause
of
cancer‐related
mortality
globally,
with
increasing
incidence
presenting
significant
treatment
challenges.
Traditional
nontargeted
therapies
often
result
in
high
toxicity
and
limited
efficacy,
underscoring
the
need
for
improved
modalities.
This
review
highlights
recent
advancements
drug
delivery
systems
to
enhance
therapeutic
outcomes
CRC.
We
examine
innovative
strategies,
including
computer‐assisted
pharmaceutical
formulation,
sustained‐release
matrices,
prodrugs,
as
well
targeted
mechanisms
such
exosomes,
liposomes,
hydrogels,
antibody‐drug
conjugates,
stimuli‐responsive
systems.
These
methodologies
offer
biodistribution,
enhanced
targeting
cells,
reduced
off‐target
effects,
promising
better
clinical
outcomes.
Additionally,
we
discuss
development
novel
formulations
designed
optimize
agents
advanced
Ongoing
trials
investigating
these
signify
shift
toward
more
effective
patient
options.
While
challenges
remain
application
therapies,
continued
research
offers
avenues
improving
study
aims
inform
future
strategies
managing
this
aggressive
disease,
ultimately
enhancing
survival
rates
quality
life
affected
individuals.
Язык: Английский
CAPECITABINE IN THE MODERN MANAGEMENT OF COLON CANCER: CLINICAL OUTCOMES AND PERSPECTIVES
Journal of Drug Delivery Science and Technology,
Год журнала:
2024,
Номер
unknown, С. 106545 - 106545
Опубликована: Дек. 1, 2024
Язык: Английский
Comprehensive analysis of bulk and single-cell RNA sequencing data reveals Schlafen-5 (SLFN5) as a novel prognosis and immunity
International Journal of Medical Sciences,
Год журнала:
2024,
Номер
21(12), С. 2348 - 2364
Опубликована: Янв. 1, 2024
Recent
advancements
have
elucidated
the
multifaceted
roles
of
Schlafen
(SLFN)
family,
including
SLFN5,
SLFN11,
SLFN12,
SLFN13,
and
SLFN14,
which
are
implicated
in
immunological
responses.
However,
little
is
known
about
this
gene
family
relation
to
malignancy
development.
The
current
study
aimed
explore
diagnostic
prognostic
potential
genes
colorectal
adenocarcinoma
(COAD)
through
bioinformatics
analysis.
Leveraging
advanced
tools
bulk
RNA-sequencing
single-cell
sequencing,
we
conducted
in-depth
analyses
expressions,
functional
enrichment,
survival
patterns
patients
with
cancer
compared
normal
tissue.
Among
genes,
transcription
levels
SLFN5
COAD
tissues
were
significantly
elevated
correlated
poor
outcomes.
Furthermore,
regulated
immune
response
via
Janus
kinase
(JAK)/signal
transduction
activator
(STAT)/interferon
(IFN)-alpha/beta
signaling.
These
chemokines
inflammation
associated
diabetes
metabolism,
suggesting
their
involvement
altered
cellular
energetics
for
progress.
In
addition,
an
cell
deconvolution
analysis
indicated
a
correlation
between
expression
immune-related
populations,
such
as
regulatory
T
cells
(Tregs).
findings
highlighted
clinical
significance
provided
insights
into
its
tumor
microenvironment
regulation.
Meanwhile,
drug
discovery
data
SFLN5
targeted
small
molecules
suggested
therapeutic
COAD.
Collectively,
research
demonstrated
that
play
crucial
development
serve
prospective
biomarker
Язык: Английский